Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways

Genmab A/S decided to file a request to review the award dismissing its claims in the second arbitration arising under its license agreement with Johnson & Johnson's Janssen Biotech Inc for Darzalex (daratumumab).